Erratum: Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab (British Journal of Cancer (2011) 104 (68-74) DOI: 10.1038/sj.bjc.6605972)

Autor: Gualberto, A., Hixon, M. L., Karp, D. D., LI BASSI, Daniele, Green, S., Dolled-Filhart, M., Paz-Ares, L. G., Novello, S., Blakely, J., Langer, C. J., Pollak, M. N.
Jazyk: angličtina
Rok vydání: 2012
Databáze: OpenAIRE